opag (P = 0.025), FIGURE. Regardless with the indication for switching, most sufferers achieved a total response (Plt10009/L) on avatrombopag (TABLE). Concomitant Medications/Rescue Therapy: With the 19 sufferers who expected concomitant corticosteroids even though on romiplostim/eltrombopag, twelve (63 ) discontinued steroids, 6 (32 ) lowered CA I Inhibitor Accession steroid dose, and none enhanced steroid dose after switching to avatrombopag. 15 Individuals (33 ) essential rescue during the 12 months just before switching versus 9 (twenty ) following the switch. Avatrombopag Discontinuation: 2 individuals (4 ) discontinued for adverse events (headache, portal vein thrombosis) and one (two ) discontinued for lack of response. TABLE one Costs of platelet response following switch to avatrombopag while in the absence of rescue treatment (counts were disqualified ATR Activator Formulation ifReason for Switch from Eltrombopag or Romiplostim to Avatrombopag Platelet Count Threshold 300 /L 5009/L 10009/L(through remedy with romiplostim or eltrombopag) vs. following the switch to avatrombopag. For every patient, the median platelet count would be the median of the most recent 3 platelet counts measured though getting that agent. (A) All sufferers (N = 45). (B) Individuals switched resulting from ineffectiveness of romiplostim or eltrombopag (N = 14). One particular patient with median Plt 58509/L on avatrombopag omitted from the two graphs to protect graph resolution Conclusions: Within a heavily-pretreated continual ITP population, avatrombopag was helpful following therapy with romiplostim or eltrombopag, with high response rates even in individuals with inadequate response to a prior TPO-RA.PB0824|Refractory Immune Thrombocytopenia (ITP): The Combination of Thrombopoietin Analogs and Immunosuppressants, Expertise in the Single Spanish Center I. S chez Baz ; S. Mart T lez; F.J. L ez Jaime; M.I. Mu z Hospital Regional de M aga, M aga, Spain Background: A compact proportion of patients with immune thrombocytopenia (ITP) don’t react to typical treatment options, they may benefit from combined therapy with thrombopoietin analogs and immunosuppressants. Aims: To describe our knowledge from the therapy of refractory ITP with combination of TPO-RA and immunosuppressants, with focus on response and safety. Solutions: We study grownups with refractory ITP taking into consideration refractoriness not reaching platelets increased than 30 x10^9/L or corticosteroid-dependence. All sufferers had been diagnosed and taken care of during the same center with mixed therapy just after failureAll Individuals (N = 45) 42/45 (93 ) 42/45 (93 ) 39/45 (87 )Ineffectiveness (N = 14) 12/14 (86 ) 12/14 (86 ) 10/14 (71 )Convenience (N = 23) 23/23 (100 ) 23/23 (a hundred ) 22/23 (96 )Adverse Event (N = 8) 7/8 (88 ) 7/8 (88 ) 7/8 (88 )ABSTRACT611 of|of monotherapy. We take into consideration total response a platelet count greater than 100 x10^9/L and response by a platelet count 3000 x10^9/L, according to your worldwide recommendations. We report adverse occasions of six weeks after the blend (infections requiring hospital admission and thromboembolic events as deep vein thrombosis and pulmonary embolism). Effects: We analyzed 13 grownup patients, 73 female, median age 52 (range 185). Two had secondary ITP, eleven had primary ITP. 4 had prior Splenectomy, not performed in 9 due to the fact of contraindication or patient refusal. At the time of mixture, median platelet count was 18 x10^9/L (43), median duration of ITP was 28 months (216). The mixture treatment incorporates a thrombopoetin analog (romiplostim or eltrombopag) with an immunosuppressant, azathiop